Labcorp Holdings Inc. (ETR:N6B)
Germany · Delayed Price · Currency is EUR | Market Cap | 20.07B +6.1% |
| Revenue (ttm) | 12.27B +7.3% |
| Net Income | 816.56M +28.8% |
| EPS | 9.79 +30.2% |
| Shares Out | n/a |
| PE Ratio | 24.58 |
| Forward PE | 15.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Open | 244.00 |
| Previous Close | 240.00 |
| Day's Range | 244.00 - 244.00 |
| 52-Week Range | 224.00 - 246.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Labcorp Holdings
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target speci... [Read more]
Financial Performance
In 2025, Labcorp Holdings's revenue was $13.95 billion, an increase of 7.25% compared to the previous year's $13.01 billion. Earnings were $876.50 million, an increase of 17.49%.
Financial numbers in USD Financial StatementsNews
Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomas Designed to reduce common barriers to at-home screening...
Labcorp Holdings Transcript: Jefferies Global Healthcare Conference 2026
Strong Q1 results led to raised full-year guidance, with growth driven by diagnostics, specialty testing, and consumer-initiated channels. AI and innovation are central to operational efficiency and portfolio expansion, while M&A targets regional labs and health systems for strategic growth.
Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
Collaborative trial with Alliance for Clinical Trials in Oncology will evaluate new approaches to increase germline genetic testing among at-risk family members Research will also assess the clinical ...
Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Pathology to support safer, more personalized cancer treatment BURLINGTON, N.C., May 28, 2026 /PRNewswir...
Labcorp to Present at the Jefferies Global Healthcare Conference
BURLINGTON, N.C., May 27, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that the company will present at the 2026 Jeffer...
Labcorp Holdings Transcript: AGM 2026
The meeting covered strong 2025 financial results, board elections, executive compensation, and auditor ratification, with all proposals passing by wide margins. Management addressed regulatory risks in animal research supply chains and affirmed operational resilience.
Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask que...
Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and spec...
Labcorp Holdings Earnings Call Transcript: Q1 2026
Q1 2026 delivered 5.8% revenue growth, 10.6% EPS growth, and margin expansion, driven by strong Diagnostics and BLS performance, specialty testing, and strategic partnerships. Guidance for 2026 was raised, with continued focus on innovation, M&A, and operational efficiency.
Labcorp Holdings Earnings release: Q1 2026
Labcorp Holdings released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Labcorp Holdings Slides: Q1 2026
Labcorp Holdings has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Labcorp Holdings Quarterly report: Q1 2026
Labcorp Holdings has published its Q1 2026 quarterly earnings report on April 30, 2026.
Labcorp raises full-year forecasts on steady diagnostics demand
Labcorp raised its full-year profit and revenue forecast on Thursday after posting quarterly results above expectations as demand for diagnostic testing remained steady.
Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
Results from Operations for first quarter 2026 versus first quarter 2025: Revenue: $3.54 billion vs. $3.35 billion, up 5.8% Diluted EPS: $3.35 vs.
Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technol...
d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth
BOSTON--(BUSINESS WIRE)--d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its Presid...
Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
First FDA-cleared rapid fentanyl test of its kind made in the United States designed to help emergency department and hospital teams act quickly when every second counts Fentanyl Urine Visual Test is ...
Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
Platform leverages agentic AI and diverse healthcare datasets to transform and speed drug development BURLINGTON, N.C., April 14, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative...
Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide
Collaboration aims to speed the discovery, development and national availability of specialized pediatric diagnostics BURLINGTON, N.C. and PHILADELPHIA, April 13, 2026 /PRNewswire/ -- Labcorp (NYSE: L...
Labcorp Holdings Proxy statement: Proxy filing
Labcorp Holdings filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Labcorp Holdings Proxy statement: Proxy filing
Labcorp Holdings filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., April 9, 2026 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has d...
Labcorp to Announce First Quarter Financial Results on April 30, 2026
BURLINGTON, N.C., March 31, 2026 /PRNewswire/ -- Labcorp Holdings Inc.
Illumina and Labcorp expand collaboration to broaden access to precision oncology testing
SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collabo...
Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide
AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patien...